Skip to main content
Log in

The prevention of contrast-induced nephropathy by minimising the contrast agent “confers significant economical benefit”

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

REFERENCE

  1. Takano H, Yamamoto E, Takano M, Takagi G, Asai K, Yasutake M, Mizuno K.Economical benefit of the prevention of contrast-induced nephropathy in patients with chronic kidney disease ESC Congress 2009: Annual Congress of the European Society of Cardiology: abstr. P1491, 29 Aug 2009. Available from: URL: http://www.escardio.org

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The prevention of contrast-induced nephropathy by minimising the contrast agent “confers significant economical benefit”. Pharmacoecon. Outcomes News 588, 10 (2009). https://doi.org/10.2165/00151234-200905880-00026

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905880-00026

Keywords

Navigation